WO2002083733A3 - Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-6 - Google Patents

Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-6 Download PDF

Info

Publication number
WO2002083733A3
WO2002083733A3 PCT/EP2002/004953 EP0204953W WO02083733A3 WO 2002083733 A3 WO2002083733 A3 WO 2002083733A3 EP 0204953 W EP0204953 W EP 0204953W WO 02083733 A3 WO02083733 A3 WO 02083733A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
polynucleotides
polypeptides
ifnalpha
new
Prior art date
Application number
PCT/EP2002/004953
Other languages
English (en)
Other versions
WO2002083733A2 (fr
Inventor
Jean-Louis Escary
Original Assignee
Genodyssee
Jean-Louis Escary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genodyssee, Jean-Louis Escary filed Critical Genodyssee
Priority to AU2002316891A priority Critical patent/AU2002316891A1/en
Publication of WO2002083733A2 publication Critical patent/WO2002083733A2/fr
Publication of WO2002083733A3 publication Critical patent/WO2002083733A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur de nouveaux polynucléotides dérivés de la séquence nucléotidique du gène IFNα-6 comprenant de nouveaux polymorphismes d'un nucléotide simple (PNS), et sur de nouveaux polypeptides dérivés de la protéine naturelle de type sauvage IFNα-6 comprenant au moins une mutation provoquée par au moins un PNS de l'invention, ainsi que sur leurs utilisations thérapeutiques.
PCT/EP2002/004953 2001-04-18 2002-04-17 Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-6 WO2002083733A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002316891A AU2002316891A1 (en) 2001-04-18 2002-04-17 Polynucleotides and polypeptides of the ifnalpha-6 gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0105239 2001-04-18
FR0105239A FR2823763A1 (fr) 2001-04-18 2001-04-18 Nouveaux polynucleotides et polypeptides de l'interferon alpha 6

Publications (2)

Publication Number Publication Date
WO2002083733A2 WO2002083733A2 (fr) 2002-10-24
WO2002083733A3 true WO2002083733A3 (fr) 2003-02-20

Family

ID=8862425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004953 WO2002083733A2 (fr) 2001-04-18 2002-04-17 Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-6

Country Status (3)

Country Link
AU (1) AU2002316891A1 (fr)
FR (1) FR2823763A1 (fr)
WO (1) WO2002083733A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202028246A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 B7h3單域抗體及其治療性組合物
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
CA3115089A1 (fr) 2018-10-11 2020-04-16 Inhibrx, Inc. Anticorps a domaine unique dll3 et compositions therapeutiques
CN113518647A (zh) 2018-10-11 2021-10-19 印希比股份有限公司 5t4单域抗体及其治疗性组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002459A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp Interferon alpha 61
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
WO2001025438A2 (fr) * 1999-10-07 2001-04-12 Maxygen, Inc. Homologues d'interferons alpha

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
WO1983002459A1 (fr) * 1982-01-15 1983-07-21 Cetus Corp Interferon alpha 61
WO2001025438A2 (fr) * 1999-10-07 2001-04-12 Maxygen, Inc. Homologues d'interferons alpha

Also Published As

Publication number Publication date
WO2002083733A2 (fr) 2002-10-24
AU2002316891A1 (en) 2002-10-28
FR2823763A1 (fr) 2002-10-25

Similar Documents

Publication Publication Date Title
WO2002085940A3 (fr) Polynucleotides et polypeptides du gene de l'erythropoietine (epo)
CY1107335T1 (el) ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17
WO2002079249A3 (fr) Nouveaux polynucleotides et nouveaux polypeptides du gene ifn$g(a)-21
WO2005001064A3 (fr) Polypeptides a activite alpha-amylase et polynucleotides codant pour ceux-ci
HUP0402271A2 (hu) Pseudoplectania nigrellá-ból származó antimikrobiális polipeptidek
EP2298872A3 (fr) Polypeptides dotés d'activité lipase et polynucléotides les codant
EP1622921A4 (fr) Variantes de beta-glucosidases
DE60235297D1 (de) Auf lps-reagierendes chs1/beige-ähnliches anker-gen und therapeutische anwendungen davon
WO2002095067A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifnα-14
WO2006005032A3 (fr) Polypeptides ayant l'activite d'alpha-glucosidase et polynucleotides les codant
WO2003000896A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-5
WO2005058945A3 (fr) Variants genetiques codant pour des proteines issues de la voie metabolique de produits chimiques fins
WO2002101048A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-7
WO2002083733A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-6
WO2003016550A3 (fr) Compositions et procedes comprenant un acide nucleique temoin
WO2002101002A3 (fr) Nouveaux polynucleotides et polypeptides du gene hgh-v
EP1236800A3 (fr) Acides nucléiques encodant l'interféron alpha 2, contenant des polymorphismes mononucléotidiques et procédés d'utilisation de ces acides
WO2000028036A3 (fr) Facteurs de resistance a la maladie
WO2002072632A3 (fr) Acides nucleiques du gene abcc11 humain, vecteurs contenant lesdits acides nucleiques et leurs utilisations
WO2002064827A3 (fr) Acides nucleiques du gene humain abca12, vecteurs contenant ces acides nucleiques, et utilisations associees
WO2000032777A3 (fr) Toxines scorpioniques
WO2003041490A3 (fr) Nouvelles isoamylases ainsi que procedes et produits associes
AU2001287860A1 (en) Transglutaminase gene products
WO2002085943A3 (fr) Acides nucleiques du gene abcc12 humain, vecteurs contenant ces acides nucleiques et utilisations associees
WO2000068406A3 (fr) Facteurs de resistance aux maladies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP